Search
Descriptor English: Sorafenib
Descriptor Spanish: Sorafenib
Descriptor sorafenib
Entry term(s) BAY 43 9006
BAY 43-9006
BAY 439006
BAY 545 9085
BAY 545-9085
BAY 5459085
BAY 673472
BAY-545-9085
BAY-673472
BAY5459085
N óxido de sorafenib
N-óxido de sorafenib
Nexavar
metiamida-4-metilbencenosulfonato del ácido 4-(4-(3-(4-cloro-3-trifluorometilfenil)ureido)fenoxi)piridina-2-carboxílico
tosilato de sorafenib
Scope note: Derivado de niacinamida y fenilurea que inhibe diversas cinasas intracelulares y de la superficie celular que se cree que intervienen en la angiogénesis, como las CINASAS RAF y los RECEPTORES DE FACTORES DE CRECIMIENTO ENDOTELIAL VASCULAR. Se usa en el tratamiento del CARCINOMA DE CÉLULAS RENALES y del CARCINOMA HEPATOCELULAR avanzados y del CÁNCER DE TIROIDES resistente al tratamiento con yodo radiactivo.
Descriptor Portuguese: Sorafenibe
Descriptor French: Sorafénib
Entry term(s): 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
BAY 43 9006
BAY 43-9006
BAY 439006
BAY 545 9085
BAY 545-9085
BAY 5459085
BAY 673472
BAY-545-9085
BAY-673472
BAY5459085
Nexavar
Sorafenib N Oxide
Sorafenib N-Oxide
Sorafenib Tosylate
Tree number(s): D02.065.950.681.757
D02.455.426.559.389.703.757
D03.066.515.530.750
D03.383.725.547.530.750
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000077157
Scope note: A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antineoplastic Agents
Protein Kinase Inhibitors
Registry Number: 9ZOQ3TZI87
CAS Type 1 Name: 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-
Public MeSH Note: 2019; SORAFENIB was indexed under NIACINAMIDE and PHENYLUREA COMPOUNDS 2014-2018, and under BENZENESULFONATES and PYRIDINES 2003-2013
History Note: 2019 (2003)
DeCS ID: 57527
Unique ID: D000077157
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2019/01/01
Date of Entry: 2018/07/09
Revision Date: 2018/01/11
Sorafenib - Preferred
Concept UI M0446095
Scope note A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.
Preferred term Sorafenib
Nexavar - Narrower
Concept UI M0493145
Preferred term Nexavar
BAY 43-9006 - Narrower
Concept UI M0446096
Preferred term BAY 43-9006
Entry term(s) BAY 43 9006
BAY 439006
Sorafenib N-Oxide - Narrower
Concept UI M000639469
Preferred term Sorafenib N-Oxide
Entry term(s) Sorafenib N Oxide
BAY-673472 - Narrower
Concept UI M000639471
Preferred term BAY-673472
Entry term(s) BAY 673472
BAY 545-9085 - Narrower
Concept UI M0536239
Preferred term BAY 545-9085
Entry term(s) BAY 545 9085
BAY 5459085
BAY-545-9085
BAY5459085
Sorafenib Tosylate - Narrower
Concept UI M0493144
Preferred term Sorafenib Tosylate
Entry term(s) 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey